Buy Pravachol (Pravastatin) Online - Hydrophilic Statin to Lower LDL Cholesterol & Prevent Heart Disease

The main modern uses of Pravachol

• 🫀 Primary cardiovascular prevention - WOSCOPS landmark evidence
• ❤️ Secondary cardiovascular prevention - CARE and LIPID trial evidence in post-MI clients
• 🩹 Transplant recipients on cyclosporine - preferred statin due to interaction profile
• 🧪 HIV clients on protease inhibitors - minimal CYP3A4 interaction
• 👵 Older adults - PROSPER trial evidence in ages 70-82
• 👶 Paediatric HeFH from age 8 - one of the few statins with early paediatric approval
• 💊 Clients on complex polypharmacy where CYP interactions are a concern
• 💰 Cost-sensitive lipid therapy - well-established generic

Primary cardiovascular prevention

In clients without established atherosclerotic cardiovascular disease (ASCVD) but at elevated risk, pravastatin reduces first MI, stroke, and cardiovascular death. Landmark evidence from WOSCOPS in men with hypercholesterolaemia and MEGA in Japanese primary prevention. Guidelines use risk calculators to identify who benefits. Section 3 covers primary prevention.

Secondary cardiovascular prevention

In clients with established ASCVD, statins substantially reduce recurrent events and mortality. Pravastatin has strong evidence in secondary prevention (CARE and LIPID trials) but is moderate intensity - for post-ACS high-risk clients, high-intensity atorvastatin or rosuvastatin is generally preferred. Pravastatin fits in stable secondary prevention where moderate intensity suits. Section 4 covers secondary prevention.

Transplant recipients on cyclosporine

This is a specific niche where pravastatin has clear advantages. Cyclosporine strongly interacts with CYP3A4-metabolised statins (atorvastatin, simvastatin, lovastatin), substantially raising statin levels and myopathy risk. Pravastatin is not CYP3A4-metabolised, though cyclosporine does raise pravastatin levels via OATP inhibition - dose limit typically 20 mg. Preferred statin in solid organ transplant recipients per multiple transplant guidelines. Section 5 covers this indication.

HIV clients on protease inhibitors

Ritonavir-boosted protease inhibitors strongly inhibit CYP3A4 - contraindicated with lovastatin and simvastatin, and significantly increasing atorvastatin exposure. Pravastatin's minimal CYP3A4 metabolism makes it a preferred statin in HIV clients on these regimens, alongside rosuvastatin.

Older adults

The PROSPER trial specifically tested pravastatin in clients aged 70-82 with cardiovascular risk factors. Pravastatin reduced cardiovascular events by 15 percent. This established evidence-based statin therapy for older adults. Well-tolerated across the geriatric age range. Section 25 covers older adult use.

Familial hypercholesterolaemia

Genetic disorder with very high LDL and premature ASCVD. Pravastatin at maximum dose alone is usually insufficient for HeFH; typically combined with ezetimibe and often PCSK9 inhibitor. FDA-approved for paediatric HeFH from age 8 - one of the few statins with such early paediatric approval.

Diabetes and cardiovascular risk reduction

Diabetes carries substantially increased cardiovascular risk. Statin therapy standard for most diabetic adults over 40. Pravastatin fits when moderate-intensity therapy is appropriate; atorvastatin often preferred when higher intensity needed.

Chronic kidney disease

Pravastatin can be used across most CKD stages. Dose reduction for severe CKD. Pravastatin has some renal excretion so extra care in end-stage renal disease. Studied in dialysis-treated ESRD in 4D and AURORA - benefit uncertain in this specific population.

Where statins do not routinely fit

• Isolated severe hypertriglyceridaemia (fibrate or icosapent ethyl more targeted)
• NYHA III-IV heart failure without CAD (CORONA and GISSI-HF neutral)
• Very short life expectancy - benefit accrues over years
• Isolated low HDL without other lipid abnormalities

Where pravastatin has specific advantages

The particular niche for pravastatin in modern practice is clients where CYP3A4 drug interactions are a concern and tolerance is prioritised over maximum LDL lowering. Transplant recipients, HIV clients on protease inhibitors, older adults on polypharmacy, and clients with prior statin muscle intolerance often do particularly well on pravastatin.

Who is typically eligible

• LDL cholesterol 190 mg/dL (4.9 mmol/L) or higher - regardless of other risk factors; likely familial hypercholesterolaemia
• Diabetes plus age 40-75 - statin therapy indicated
• 10-year ASCVD risk 7.5-20 percent or higher depending on individual factors
• Hypercholesterolaemia in middle-aged men (WOSCOPS population)
• Chronic kidney disease stage 3 or worse
• Chronic inflammatory conditions (SLE, RA, HIV)
• Family history of premature ASCVD
• Elevated coronary calcium score

The WOSCOPS trial

The West of Scotland Coronary Prevention Study (Shepherd et al. NEJM 1995) enrolled 6,595 men aged 45-64 with LDL cholesterol 155-232 mg/dL (4.0-6.0 mmol/L) and no history of MI. Randomised to pravastatin 40 mg or placebo. Mean follow-up 4.9 years. Coronary events reduced by 31 percent (definite non-fatal MI or coronary death). Cardiovascular mortality reduced 32 percent. All-cause mortality reduced 22 percent (borderline significant). Established primary prevention benefit in hypercholesterolaemic middle-aged men. WOSCOPS has been one of the most influential primary prevention trials in cardiovascular medicine.

WOSCOPS 20-year follow-up

Ford and colleagues extended WOSCOPS to 20 years of follow-up (Circulation 2016). The mortality benefit persisted long after the trial ended - clients originally randomised to pravastatin had lower coronary heart disease mortality, lower cardiovascular mortality, and lower all-cause mortality decades later. This provides remarkable evidence that early statin therapy provides durable benefit years beyond active treatment - the "legacy effect".

MEGA Study - Asian primary prevention

• Published Lancet 2006, Nakamura and colleagues
• Japanese men and women, 40-70 years old
• 7,832 clients with moderate hypercholesterolaemia (total cholesterol 220-270 mg/dL)
• Low-dose pravastatin (10-20 mg) plus diet vs diet alone
• Coronary events reduced 33 percent
• Extended primary prevention evidence to Asian populations at lower statin doses

Typical primary prevention regimen

• Pravastatin 40 mg once daily (moderate intensity per WOSCOPS)
• Lower doses (10-20 mg) may suit in less severe dyslipidaemia or Asian populations
• LDL target for primary prevention typically under 100 mg/dL (2.6 mmol/L)
• Lower targets in higher-risk primary prevention (diabetes with organ damage, familial hypercholesterolaemia)
• Combined with lifestyle - diet, exercise, weight, smoking cessation
• Blood pressure management alongside
• Ongoing cardiovascular risk factor review

Setting realistic expectations

• Statins reduce first-event risk by roughly 25-30 percent
• Absolute risk reduction depends on baseline risk
• Benefit accrues over years - not visible immediately
• Combined with lifestyle for best effect
• Long-term commitment typical
• Legacy effect - continued benefit even years after therapy stops (WOSCOPS 20-year evidence)

Who needs secondary prevention

• Prior myocardial infarction
• Prior ischaemic stroke or TIA (atherothrombotic)
• Prior coronary revascularisation (PCI or CABG)
• Documented CAD on imaging
• Peripheral arterial disease
• Aortic atherosclerotic disease
• Symptomatic carotid disease
• Polyvascular disease (highest-risk group)

CARE Trial - the average cholesterol landmark

The Cholesterol and Recurrent Events trial (Sacks et al. NEJM 1996) enrolled 4,159 clients with prior MI and average total cholesterol under 240 mg/dL, LDL 115-174 mg/dL. Randomised to pravastatin 40 mg or placebo. Mean follow-up 5 years. Major coronary events reduced by 24 percent. Stroke reduced 31 percent. Established that clients with only average cholesterol still benefit from statin therapy after MI - a fundamental shift that broadened secondary prevention indication.

LIPID Trial - the mortality confirmation

The Long-Term Intervention with Pravastatin in Ischaemic Disease trial (NEJM 1998) enrolled 9,014 clients aged 31-75 with prior MI or unstable angina hospitalisation, total cholesterol 155-271 mg/dL. Randomised to pravastatin 40 mg or placebo. Mean follow-up 6.1 years. Coronary heart disease mortality reduced by 24 percent. All-cause mortality reduced 22 percent. Established durable secondary prevention mortality benefit with pravastatin.

Where pravastatin fits in secondary prevention

• Stable coronary disease with moderate-intensity requirement - pravastatin 40-80 mg
• Transplant recipients on cyclosporine - preferred statin
• HIV clients on protease inhibitors - one of two preferred choices (rosuvastatin the other)
• Statin-intolerant clients who tolerate pravastatin - often useful
• Older adults - PROSPER trial evidence
• Cost-sensitive scenarios - generic pravastatin cheap
• Long-standing stable therapy that has been well-tolerated for years - continuation reasonable

Where atorvastatin or rosuvastatin is preferred over pravastatin

• Recent acute coronary syndrome - high-intensity therapy (PROVE-IT and TNT evidence)
• Very high-risk clients - LDL target under 55 mg/dL requires high-intensity therapy
• Familial hypercholesterolaemia with established ASCVD - maximum LDL reduction needed
• Polyvascular disease - highest-risk group
• Recurrent events on moderate-intensity therapy

LDL targets for secondary prevention

Transplant recipients on cyclosporine

• Cyclosporine strongly inhibits CYP3A4 - dramatic effect on lovastatin, simvastatin, atorvastatin levels
• Cyclosporine also inhibits OATP1B1 - the transporter statins use to enter hepatocytes
• All statins have raised levels with cyclosporine, but pravastatin has fewest interactions
• Pravastatin preferred at reduced dose (typically 20 mg maximum)
• Standard first-choice statin in solid organ transplant guidelines
• Monitor CK if muscle symptoms

Cardiovascular risk in transplant recipients

Post-transplant clients have substantially elevated cardiovascular risk from multiple factors: pre-transplant disease, immunosuppression effects on lipids, corticosteroid-driven diabetes and hypertension, calcineurin inhibitor cardiovascular effects. Statin therapy is a standard part of long-term post-transplant care. Renal, cardiac, liver, and other solid organ transplant recipients all benefit from lipid management.

HIV clients on protease inhibitors

• Ritonavir-boosted protease inhibitors strongly inhibit CYP3A4
• Lovastatin, simvastatin contraindicated with these regimens
• Atorvastatin significantly elevated; dose limits apply
• Pravastatin - minimal interaction; preferred statin in many HIV guidelines
• Rosuvastatin also acceptable (also non-CYP3A4)
• HIV-associated dyslipidaemia and increased cardiovascular risk make statin often needed
• HIV specialist input essential

Older adults with polypharmacy

• Fewer CYP3A4 interactions reduces polypharmacy concerns
• Simpler management around new medications
• PROSPER trial specifically demonstrated benefit in 70-82 year olds
• Well-tolerated across geriatric populations

Statin-intolerant clients (particularly muscle)

• Hydrophilic nature means less muscle tissue penetration than lipophilic statins
• Some observational data suggests lower rate of muscle complaints
• Often worth trying when muscle symptoms have occurred on atorvastatin or simvastatin
• Rosuvastatin also hydrophilic and often tried

Chronic kidney disease

• Can be used across most CKD stages
• Dose reduction (10-20 mg) for severe CKD
• Some renal excretion so caution in end-stage renal disease
• Studied in dialysis populations (4D with atorvastatin; SHARP with simvastatin/ezetimibe)
• Benefit in ESRD less clear

Paediatric HeFH from age 8

• FDA-approved for children with heterozygous FH from age 8
• One of the earliest paediatric approvals in the statin class
• Growth, puberty, long-term safety reasonably documented
• Paediatric lipid specialist involvement
• Starting dose 20 mg once daily; adjust based on LDL

Why pravastatin fits these populations

The common thread across transplant, HIV, elderly polypharmacy, and paediatric use is that predictability and low interaction risk matter more than maximum LDL reduction. Pravastatin's hydrophilic chemistry, non-CYP3A4 metabolism, established long-term safety record, and paediatric FDA approval all serve this common need. For clients where high-intensity therapy is essential (recent ACS, very high LDL familial hypercholesterolaemia), atorvastatin or rosuvastatin remains preferred despite the CYP concerns.

WOSCOPS - the primary prevention landmark

• West of Scotland Coronary Prevention Study
• Published NEJM 1995, Shepherd and colleagues
• 6,595 men aged 45-64 with hypercholesterolaemia
• No history of MI
• Pravastatin 40 mg vs placebo
• Mean follow-up 4.9 years
• Coronary events reduced 31 percent
• Cardiovascular mortality reduced 32 percent
• All-cause mortality reduced 22 percent
• Landmark primary prevention evidence

WOSCOPS 20-year follow-up

• Published Circulation 2016, Ford and colleagues
• Extended observational follow-up
• Persistent all-cause mortality benefit
• Persistent coronary heart disease mortality benefit
• Evidence of durable "legacy effect" from early statin therapy

CARE - average cholesterol secondary prevention

• Cholesterol and Recurrent Events
• Published NEJM 1996, Sacks and colleagues
• 4,159 clients with prior MI
• Average cholesterol at baseline (under 240 mg/dL total)
• Pravastatin 40 mg vs placebo
• Mean follow-up 5 years
• Major coronary events reduced 24 percent
• Stroke reduced 31 percent
• Established statin benefit even at average cholesterol levels

LIPID - long-term secondary prevention

• Long-Term Intervention with Pravastatin in Ischaemic Disease
• Published NEJM 1998
• 9,014 clients with prior MI or unstable angina hospitalisation
• Total cholesterol 155-271 mg/dL
• Pravastatin 40 mg vs placebo
• Mean follow-up 6.1 years
• Coronary heart disease mortality reduced 24 percent
• All-cause mortality reduced 22 percent
• Established durable secondary prevention mortality benefit

PROSPER - elderly evidence

• PROspective Study of Pravastatin in the Elderly at Risk
• Published Lancet 2002, Shepherd and colleagues
• 5,804 clients aged 70-82
• History of cardiovascular disease or risk factors
• Pravastatin 40 mg vs placebo
• Mean follow-up 3.2 years
• Composite CV endpoint reduced 15 percent
• Established evidence-based statin therapy for older adults
• Balanced elderly-specific concerns

ALLHAT-LLT - the pragmatic comparison

• Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial - Lipid-Lowering Trial
• Published JAMA 2002
• 10,355 hypertensive clients with moderate hypercholesterolaemia
• Pravastatin 40 mg vs usual care
• Neutral primary result - attributed to control-group crossover to open-label statin
• Highlighted difficulty of pragmatic trials in the statin era

MEGA - Japanese primary prevention

• Published Lancet 2006, Nakamura and colleagues
• 7,832 Japanese clients
• Low-dose pravastatin (10-20 mg) plus diet vs diet alone
• Coronary events reduced 33 percent
• Extended evidence to Asian populations at lower doses

PROVE-IT TIMI 22 - the comparator role

• Published NEJM 2004, Cannon and colleagues
• 4,162 clients after acute coronary syndrome
• Atorvastatin 80 mg vs pravastatin 40 mg
• Atorvastatin high-dose superior for post-ACS
• Established high-intensity statin as post-ACS standard
• Positioned pravastatin as moderate-intensity where high-intensity is preferred

The overall picture

Pravastatin has among the strongest and longest-running trial evidence in the statin class - across primary prevention (WOSCOPS, MEGA), secondary prevention (CARE, LIPID), and elderly (PROSPER). The 20-year WOSCOPS follow-up provides unusual reassurance about durable benefit. The comparator role in PROVE-IT positioned pravastatin as moderate-intensity in the modern intensity-based classification. All these trials together define pravastatin's modern niche as a moderate-intensity statin with strong evidence base and favourable interaction profile.

The HMG-CoA reductase pathway

1. HMG-CoA reductase catalyses conversion of HMG-CoA to mevalonate
2. Mevalonate is precursor for cholesterol, ubiquinone, and other isoprenoids
3. Pravastatin competitively inhibits HMG-CoA reductase in hepatocytes
4. Hepatic cholesterol synthesis slows
5. Reduced intracellular cholesterol triggers upregulation of LDL receptors on hepatocyte surface
6. More LDL cleared from blood
7. Circulating LDL falls substantially

What distinguishes pravastatin

• Hydrophilic (water-soluble) - not fat-soluble
• Active drug (not a prodrug) - no liver activation needed
• Liver-selective - taken into hepatocytes via OATP1B1; poor penetration of other tissues
• Not metabolised by CYP3A4 - key advantage for drug interactions
• No significant grapefruit juice interaction
• Short parent drug half-life - 2 hours; steady state within days
• Renal and biliary elimination - roughly 20 percent renal
• Any-time dosing - though traditional bedtime timing persists

Hydrophilic vs lipophilic - practical implications

Pharmacokinetics

• Oral bioavailability - approximately 17 percent
• Absorption - rapid; reduced 30 percent when taken with food; usually not clinically significant
• Peak plasma concentration - 1-1.5 hours after dose
• Half-life - approximately 2 hours (parent drug)
• Protein binding - moderate (approximately 50 percent - low compared with other statins)
• Metabolism - not extensively metabolised; minimal CYP3A4 involvement; some sulphation
• Elimination - roughly 20 percent renal; rest biliary and faecal
• Steady state - within a few days

Pleiotropic effects beyond LDL

• Anti-inflammatory - hsCRP reduction
• Endothelial function improvement
• Modest antithrombotic effects
• Whether pleiotropic effects are smaller for pravastatin than lipophilic statins is debated
• Clinical outcome data at equipotent LDL reduction similar across statins

Standard dosing

Expected LDL reduction by dose

Timing flexibility

Traditionally taken at bedtime like other short-acting statins. Modern practice recognises that any consistent daily time works - the short half-life and continuous LDL receptor upregulation effect mean timing is less critical than clinicians once thought. With or without food acceptable (food modestly reduces absorption but not clinically significant). Take at whatever time supports best adherence.

Titration approach

1. Start at appropriate dose based on LDL, indication, and specific population
2. Check LDL response at 6-12 weeks
3. If not at target - increase dose or add ezetimibe
4. Recheck LDL 6-12 weeks after each change
5. If maximum pravastatin plus ezetimibe still not at target - consider switching to atorvastatin or rosuvastatin high-intensity
6. Once at target, monitor annually

Duration

• Lifelong for established ASCVD or familial hypercholesterolaemia
• Primary prevention duration individualised - benefit accrues over years
• Do not stop for uncertainty - discuss with treating team
• Reassess annually whether continuation justified

Typical initiation experience

• Most clients notice nothing subjectively in first days
• LDL reduction begins within 1 week; substantial by 2-4 weeks
• Full effect on LDL by 4-6 weeks
• Muscle symptoms less common than with lipophilic statins in some data
• Very rare early rhabdomyolysis if it occurs warrants urgent evaluation
• Long-term tolerance for the great majority

Pre-treatment assessment

• Baseline lipid profile
• Baseline liver function tests (ALT)
• Baseline HbA1c or fasting glucose
• Baseline renal function
• TSH - treat hypothyroidism first
• Review of concurrent medications - particularly cyclosporine, clarithromycin
• Fibrate history
• Discussion of expected benefits and side effect possibilities

Setting expectations

• No immediate symptom improvement - not for symptoms
• LDL reduction is the marker of success
• Long-term cardiovascular event reduction is the outcome
• Muscle symptoms - report but do not immediately assume drug-caused
• Nocebo effect substantial - clients who expect side effects experience more
• Very few clients truly cannot tolerate statins
• No grapefruit juice avoidance needed (unlike lovastatin, simvastatin, atorvastatin)
• Timing flexible

Follow-up schedule for initiation

• 6-12 weeks after start - lipid panel; LFTs
• If at target: continue current dose
• If not at target: increase dose or add ezetimibe
• Symptom review at each contact
• CK check if muscle symptoms reported
• 6-12 months for full stabilisation and long-term plan

Warning signs during initiation

• 🔴 Severe unexplained muscle pain, weakness, or tenderness
• 🔴 Dark tea-coloured urine (rhabdomyolysis)
• 🔴 Rapid CK rise (over 10x upper normal)
• 🔴 Yellow skin or eyes - liver concern
• 🔴 Persistent nausea and abdominal pain with elevated ALT
• 🔴 Rash or allergic reaction

Factors affecting individual response

• Baseline LDL - higher baseline allows more absolute reduction
• Genetics - LDL receptor variants; SLCO1B1 variants affect statin uptake
• Adherence - most common cause of "non-response"
• Diet - high-saturated-fat diet limits benefit
• Body weight, age - modest effects
• Concurrent drugs affecting OATP1B1 (cyclosporine, some HIV meds) - raise levels
• CYP3A4 modulators - much less effect than for other statins

Common dose adjustments

Non-response investigation

If LDL not falling as expected:

1. Check adherence honestly
2. Verify timing consistency
3. Rule out hypothyroidism
4. Review dietary compliance
5. Consider genetic causes (familial hypercholesterolaemia)
6. Add ezetimibe (roughly 20 percent additional LDL reduction)
7. Consider switching to atorvastatin or rosuvastatin for higher-intensity therapy
8. PCSK9 inhibitor for very high-risk

Practical daily routine

• Once daily at same time each day
• Any time of day - morning, evening, or bedtime; consistency matters more than exact time
• With water - a full glass
• With or without food - food modestly reduces absorption but not clinically significant
• Swallow whole - do not crush or chew
• Grapefruit juice acceptable - unlike lovastatin, simvastatin, atorvastatin
• Refill 2 weeks before running out

Anchor the dose to a daily habit

• Morning with breakfast or coffee
• Evening with dinner
• Bedtime with nighttime routine (traditional preference)
• Alongside other daily medications
• Weekly pillbox helpful for polypharmacy
• Phone alarm labelled "Pravachol" or "statin"

Common medication safety issues

• 🔴 Do not stop suddenly without discussion - cardiovascular risk returns
• 🔴 Report new muscle pain or weakness
• 🔴 Report dark urine - rhabdomyolysis concern
• 🔴 Never double up on missed dose
• 🔴 Alert medical team about starting cyclosporine or clarithromycin
• 🔴 Never combine with gemfibrozil (contraindicated per some sources)
• 🔴 If pregnancy considered - discuss (Section 28)

Storage

• Room temperature under 25 C
• Original packaging
• Protect from moisture
• Not in bathroom or hot car
• Out of reach of children
• Do not use past expiry
• Return unused tablets to pharmacy

Good news - no grapefruit concern

Pravastatin is not metabolised by CYP3A4, the enzyme system that grapefruit juice inhibits. Grapefruit juice consumption does not raise pravastatin levels. This is a distinct advantage over lovastatin, simvastatin, and atorvastatin where grapefruit juice interaction is substantial. Clients on pravastatin can enjoy grapefruit and grapefruit juice normally.

Pravastatin absorption

• Absorption modestly reduced by food (roughly 30 percent reduction in AUC)
• Not usually clinically significant
• Consistent timing relative to meals is more important than fasting vs fed state
• No specific food to avoid
• No dairy interaction

Cardioprotective dietary pattern

• Mediterranean-style eating - fruits, vegetables, whole grains, legumes, nuts, fish, olive oil
• Reduce saturated fat - limit red and processed meat, high-fat dairy, tropical oils
• Avoid trans fats - hydrogenated oils, some processed foods
• Sodium under 2,300 mg daily (1,500 mg if hypertensive)
• Soluble fibre - oats, barley, legumes, fruits (aids LDL reduction)
• Plant stanols/sterols - roughly 2 g daily can add 5-10 percent LDL reduction
• Fish twice weekly for omega-3
• Sugar limitation - especially sugar-sweetened beverages

Statin does not replace diet

• Diet independently affects LDL, HDL, triglycerides, glucose, blood pressure
• Diet effects add to statin effects
• Poor diet may attenuate statin LDL reduction
• Diet plus statin better than either alone

Other food and drink considerations

• Coffee and tea - fine, no interaction
• All fruit juices - safe including grapefruit
• Herbal teas mostly fine (St John Wort minor concern - Section 20)
• Dairy - no interaction (bile acid sequestrants affect calcium absorption separately)
• Alcohol - see Section 13

Alcohol interactions

• Liver - both alcohol and pravastatin processed by liver; heavy alcohol raises ALT independently and compounds statin transaminitis
• Muscle - heavy alcohol raises rhabdomyolysis risk (independent muscle toxicity)
• Triglycerides - alcohol raises triglycerides significantly
• Cardiovascular disease - heavy drinking increases cardiovascular risk

Practical guidance

Standard drink definitions

• US: 14 g pure alcohol - 12 oz beer, 5 oz wine, 1.5 oz spirits
• UK unit: 8 g pure alcohol - about 76 ml of 12 percent wine
• Weekly limits: 14 units UK; roughly similar for daily 1 US drink
• WHO 2023: No level of alcohol is without health impact

Common side effects (1-10 percent)

• Muscle symptoms - myalgia, cramps (nocebo-heavy; Section 15)
• Gastrointestinal - nausea, dyspepsia, constipation, diarrhoea
• Headache
• Elevated LFTs - usually asymptomatic
• Small blood glucose rise
• Rash - uncommon

Uncommon side effects (0.1-1 percent)

• Fatigue
• Sleep disturbance
• Hair thinning (rare)
• Sexual dysfunction (rare, likely nocebo in most cases)
• CK elevation without symptoms
• New-onset diabetes
• Reversible cognitive effects (Section 19)

Serious rare (under 0.1 percent)

• 🔴 Rhabdomyolysis (Section 16)
• 🔴 Severe hepatitis (very rare)
• 🔴 Immune-mediated necrotising myopathy (very rare autoimmune reaction)
• 🔴 Severe skin reactions (very rare)
• 🔴 Interstitial lung disease (extremely rare)

The nocebo effect is real

The SAMSON trial (2020) demonstrated that 90 percent of statin-attributed muscle complaints in symptomatic clients are not actually caused by the drug. Symptom scores on placebo tablets were nearly identical to atorvastatin - both substantially higher than no tablet. Findings apply to the statin class including pravastatin. This has fundamentally reframed how the medical community views statin intolerance complaints.

General approach to side effects

• Report new symptoms - do not assume drug-related
• Investigate other causes (exercise, medications, viral illness)
• Consider dose reduction or drug holiday for muscle symptoms
• Consider switching statin if pravastatin appears to be the cause
• Rechallenge is very often successful
• True statin intolerance is rare

Spectrum of statin muscle findings

• Myalgia - muscle pain or aching; normal CK; most common
• Myopathy - muscle symptoms plus CK 3-10x upper limit
• Severe myopathy - CK over 10x upper limit; muscle weakness
• Rhabdomyolysis - CK typically over 40x upper limit; myoglobinuria; renal injury (Section 16)
• Immune-mediated necrotising myopathy - autoimmune; anti-HMGCR antibodies; requires immunosuppression

Actual trial rates

• Randomised trials: muscle symptom rate similar to placebo
• Attributable rate to pravastatin: modestly below placebo in some analyses
• Real-world observational studies: possibly lower muscle complaint rate than atorvastatin/simvastatin
• SAMSON trial: 90 percent of complaints attributable to nocebo
• Serious myopathy very rare
• Rhabdomyolysis 1-2 per 10,000 treated years

Why pravastatin muscle symptoms may be lower

• Hydrophilic - does not readily penetrate muscle tissue
• Liver-selective uptake via OATP1B1
• Not CYP3A4-metabolised - fewer drug-drug interactions raising levels
• No grapefruit juice interaction
• Rosuvastatin (also hydrophilic) shares these features
• Often the "statin of choice" for clients with prior statin muscle intolerance

Risk factors for statin myopathy

• Advanced age (over 75)
• Female sex
• Low body weight
• Frailty
• Chronic kidney disease
• Untreated hypothyroidism
• Vitamin D deficiency
• High-intensity dose (80 mg)
• Cyclosporine coadministration
• Combined with fibrate (particularly gemfibrozil)
• Genetic - SLCO1B1 variants

Management approach to muscle symptoms

1. Assess symptom characteristics - proximal muscles more suggestive; distal often mechanical
2. Check CK
3. Check TSH (hypothyroidism)
4. Review other medications
5. Consider mechanical causes
6. If CK normal and symptoms tolerable - continue and monitor
7. If CK moderately elevated - reduce dose; recheck
8. If severe symptoms or CK over 10x - stop
9. If persistent after stopping - investigate other causes
10. After resolution - rechallenge often succeeds
11. Consider alternate-day or low-dose regimen if muscle sensitive
12. Ezetimibe alone or with lower statin dose for the truly intolerant
13. PCSK9 inhibitor or bempedoic acid for the very intolerant

🔴 What is rhabdomyolysis

Massive skeletal muscle cell breakdown releases myoglobin, potassium, and creatine kinase into circulation. Myoglobin causes acute tubular necrosis and acute kidney injury. Hyperkalaemia can cause fatal arrhythmia. Untreated severe rhabdomyolysis is life-threatening.

Warning signs

• Severe muscle pain - often unlike ordinary aches; disabling
• Muscle weakness - difficulty walking, rising, lifting
• Muscle tenderness or swelling
• Dark tea-coloured or brown urine - myoglobinuria; key warning
• Reduced urine output - AKI developing
• Malaise, nausea, fever
• Confusion - electrolyte disturbance

Emergency action

Stop pravastatin immediately. Attend emergency department without delay. Expect labs (CK, creatinine, potassium, phosphate, urinalysis), aggressive IV fluid resuscitation, cardiac monitoring, urine alkalinisation in some cases, dialysis if AKI severe. Most clients recover fully with prompt treatment.

Frequency in perspective

• Overall statin rhabdomyolysis: 1-2 per 10,000 client-years
• Pravastatin rate at bottom of statin class
• Slightly higher with 80 mg than lower doses
• Higher with cyclosporine coadministration
• Higher with fibrate combinations
• Higher in elderly and frail
• Absolute risk very low; cardiovascular benefit substantially outweighs

Risk reduction strategies

• Dose limit with cyclosporine (10-20 mg maximum)
• Dose limit with clarithromycin (40 mg maximum)
• Avoid combination with gemfibrozil
• Fenofibrate combination possible but monitor
• Assess renal function periodically
• Treat hypothyroidism
• Educate clients to recognise warning signs
• Stop temporarily during severe illness with muscle involvement

Transaminase pattern

• ALT elevation to under 3x upper normal - roughly 1-2 percent of clients; not clinically significant; continue therapy
• ALT 3x upper normal - roughly 0.5-1 percent; investigate; may reduce dose
• ALT over 3x normal - roughly 0.1-0.5 percent; require action
• Symptomatic hepatotoxicity - rare; nausea, jaundice, pain; stop
• Fulminant liver failure - extremely rare; historical case reports

Modern LFT monitoring approach

2012 FDA revised statin labels no longer recommend routine periodic LFT monitoring:

• Check baseline ALT before starting
• Check ALT if symptoms suggestive (nausea, jaundice, RUQ pain, dark urine)
• Check periodically only if concurrent liver disease
• Do not check routinely just because on statin

This reflected the recognition that mild transaminitis rarely indicates real liver damage and does not require the drug to stop.

If ALT rises

1. Verify with repeat
2. Ask about alcohol, new medications, herbal supplements
3. Check hepatitis serology if elevated ALT
4. Check for fatty liver
5. If clearly statin-related and severe - stop; consider rechallenge later
6. If mild and reversible - often continue at reduced dose

Special populations

• Fatty liver - statin actually often improves NAFLD; not contraindicated
• Compensated cirrhosis - statin often safe; benefit often exceeds risk
• Decompensated cirrhosis - contraindicated
• Hepatitis B or C - statin usually safe with monitoring
• Autoimmune hepatitis - specialist input

The evidence

• Multiple meta-analyses confirm modest increase in diabetes diagnosis on statins
• Relative risk roughly 1.1-1.2 (10-20 percent increase)
• Absolute risk: roughly 1 additional diabetes case per 250-500 client-years of statin therapy
• Pravastatin may have modestly smaller effect than some other statins
• WOSCOPS actually suggested pravastatin reduced new-onset diabetes in that population - subject of interpretation debate
• Higher risk in clients already prediabetic

Benefit-risk balance

For every additional diabetes case caused by statin therapy, approximately 5-10 cardiovascular events are prevented. Cardiovascular events matter more than the diabetes label for hard outcomes. Additionally, clients diagnosed with diabetes while on statin still benefit from that statin - the diagnosis is often the surfacing of pre-existing metabolic tendency rather than de novo disease.

Practical implications

• Do not withhold statin because of diabetes concern in appropriate clients
• Monitor glucose or HbA1c annually in clients on statin
• Emphasise diet, weight, and exercise to reduce diabetes risk independently
• If diabetes develops on statin - treat as usual; continue statin
• Diabetic clients need statin arguably more than non-diabetic clients

What was reported

• Post-marketing reports of memory loss and confusion in some clients on statins
• FDA added warning to statin labels in 2012
• Symptoms typically reversible on stopping
• Basis for warning was post-marketing surveillance not randomised trials

What subsequent evidence shows

• Large randomised trials show no meaningful cognitive effect from statins
• Multiple observational studies suggest statins may modestly REDUCE dementia risk (or be neutral)
• PROSPER trial specifically assessed cognitive function in older adults on pravastatin - no meaningful cognitive change
• 2018 STAREE trial supports safety in older adults
• 2021 STOMP trial showed no cognitive difference
• Modern consensus: statins do not cause meaningful population-level cognitive harm

Approach if cognitive symptoms occur

• Investigate other causes - sleep, mood, other medications, systemic illness
• Formal cognitive assessment if suggestive of true impairment
• Reduce dose or switch statin
• Trial off statin 1-2 months to see if symptoms improve
• If clearly improved off statin - discuss whether to continue with alternative agent
• If unchanged off statin - the cause is elsewhere; resume statin

The favourable CYP profile

Pravastatin is not significantly metabolised by CYP3A4, CYP2C9, or other major CYP enzymes. This means most of the interactions that concern lovastatin, simvastatin, and atorvastatin do NOT apply to pravastatin. No grapefruit juice concern. No significant interaction with macrolide antibiotics (except clarithromycin which affects OATP1B1). No interaction with azole antifungals. Substantial advantage for polypharmacy clients.

OATP1B1 inhibitors - the main interactions

• Cyclosporine - substantially raises pravastatin levels; dose limit 20 mg
• Clarithromycin - raises pravastatin levels; dose limit 40 mg
• Gemfibrozil - raises pravastatin levels; often avoided in combination
• Rifampicin (acute) - transporter effect; less concern chronically

Other significant interactions

• Warfarin - modest INR change possible; monitor
• Digoxin - minor increase; usually not clinically significant
• Colchicine - additive myopathy risk; use with caution
• Fibrates - myopathy risk (especially gemfibrozil); Section 22
• Cholestyramine and colestipol - reduce pravastatin absorption; separate dosing by 4 hours
• Erythromycin - modest effect via OATP1B1; monitor if higher doses

Drugs where pravastatin is FINE (unlike other statins)

• Grapefruit juice - no interaction (vs substantial with lipophilic statins)
• Itraconazole, ketoconazole (systemic) - minor concern (vs contraindicated with lovastatin/simvastatin)
• HIV protease inhibitors (ritonavir-boosted) - one of few statins acceptable
• Diltiazem, verapamil, amiodarone - little concern (vs dose limits with lovastatin)
• Fluconazole - no significant concern
• Most CYP3A4-metabolised drugs - no interaction

Herbal and supplement considerations

• St John Wort - minor effect on pravastatin (major effect on other statins)
• Red yeast rice - contains lovastatin-like compounds; do not stack
• Bergamot - minor lipid effect; unclear pravastatin interaction
• Statin-mimicking supplements - unpredictable; avoid

Cyclosporine coadministration

• Cyclosporine strongly inhibits OATP1B1 (the transporter statins use to enter hepatocytes)
• Pravastatin AUC increases roughly 5-10 fold with cyclosporine
• Muscle risk correspondingly elevated
• Approach: pravastatin maximum 20 mg daily with cyclosporine
• Monitor CK if symptoms; monitor renal function
• Pravastatin remains the preferred statin in cyclosporine transplant recipients despite the interaction - fluvastatin is another option

Why pravastatin still preferred in transplant despite interaction

The other statins have interactions with cyclosporine that are worse. Lovastatin and simvastatin have very large AUC increases and are effectively contraindicated. Atorvastatin exposure rises substantially and requires dose limits. Pravastatin at a reduced dose remains manageable and has good post-transplant lipid outcome data. Rosuvastatin is another acceptable option in cyclosporine transplant recipients but has similar OATP1B1 concerns.

Macrolide antibiotics

Compare with lovastatin/simvastatin

With lovastatin and simvastatin, clarithromycin is essentially contraindicated because CYP3A4 inhibition dramatically raises statin levels. With pravastatin, the interaction is via OATP1B1 - real but more manageable, allowing dose limitation rather than avoidance. This is one of the practical advantages of pravastatin in real-world polypharmacy.

Azole antifungals

• Itraconazole, ketoconazole (systemic), posaconazole - minimal concern with pravastatin (contraindicated with lovastatin/simvastatin)
• Fluconazole - no significant concern
• Voriconazole - minimal concern
• Terbinafine - no concern
• Pravastatin is often the preferred statin when systemic antifungal therapy is needed

HIV and HCV antivirals

• Ritonavir-boosted protease inhibitors - pravastatin acceptable (rosuvastatin also)
• Cobicistat regimens - pravastatin acceptable
• HCV direct-acting antivirals - most compatible with pravastatin (check specific product)
• Efavirenz - may modestly reduce pravastatin effect
• HIV specialist input recommended

🔴 Gemfibrozil - use with caution or avoid

Gemfibrozil substantially raises pravastatin levels through OATP1B1 inhibition. Combined rhabdomyolysis risk is elevated - not to the extent seen with lovastatin/simvastatin combinations but still meaningful. Fenofibrate is preferred over gemfibrozil when a fibrate-statin combination is needed with pravastatin.

Fibrate combinations

• Fenofibrate + pravastatin - acceptable combination; monitor CK; modest additive myopathy risk
• Gemfibrozil + pravastatin - use with caution or avoid; consider fenofibrate instead
• When needed - severe hypertriglyceridaemia with mixed dyslipidaemia
• Alternative for hypertriglyceridaemia - icosapent ethyl, omega-3 fatty acids

Cyclosporine

• Substantial pravastatin AUC elevation
• Dose limit 20 mg maximum
• Monitor CK if symptoms
• Standard preferred statin in transplant clients despite the interaction
• Transplant physician input essential
• See Section 21 for details

Other combination considerations

• Colchicine - shared myopathy risk; caution with combination
• Niacin - modest additive lipid effect; small muscle signal in combination; used in some scenarios
• Daptomycin - additive myopathy risk during course
• Danazol - modest interaction; use lower pravastatin dose

Modern lipid combination therapy

• Pravastatin + ezetimibe - well-tolerated; additive LDL reduction; standard escalation
• Pravastatin + PCSK9 inhibitor - no shared toxicity; standard for very-high-risk when higher-intensity statin not tolerated
• Pravastatin + bempedoic acid - modest additive; useful in muscle-sensitive clients
• Pravastatin + icosapent ethyl - for high triglycerides + CV risk per REDUCE-IT
• Pravastatin + inclisiran - twice-yearly PCSK9 siRNA; specialist use

The rules

• Take when you remember same day - up to 12 hours after missed time is generally fine
• If closer to next dose - skip the missed dose - resume regular schedule
• Never double up - two doses at once do not compensate
• Occasional missed doses do not derail therapy
• Frequent misses reduce effectiveness - address adherence

If several days missed

• Restart at usual dose
• No dose increase or catch-up needed
• LDL will re-fall to therapeutic range within days-weeks
• Note the cause of the gap - refill delay, forgetfulness, deliberate stop

Improving adherence

• Anchor dose to daily habit - meal, tooth brushing, bedtime
• Weekly pillbox helpful for polypharmacy
• Phone alarms or medication apps
• Order refills before running out
• Blister packaging when memory is challenging
• Address side effect concerns openly - do not silently stop

Typical monitoring schedule

LDL targets summary

• Primary prevention (moderate risk) - under 100 mg/dL (2.6 mmol/L)
• Primary prevention (high risk, diabetes) - under 70 mg/dL (1.8 mmol/L)
• Secondary prevention (established ASCVD) - under 70 mg/dL (1.8 mmol/L)
• Very high risk (recent event, polyvascular) - under 55 mg/dL (1.4 mmol/L)
• Very very high risk (recurrent events) - under 40 mg/dL (1.0 mmol/L) considered
• ApoB targets (alternative) - approximately parallel to LDL targets

When pravastatin cannot reach target

Pravastatin at maximum dose (80 mg) achieves roughly 36-37 percent LDL reduction. For clients whose target requires 50 percent or more reduction, pravastatin alone is often insufficient. Options: add ezetimibe (25 percent additional reduction), switch to atorvastatin 40-80 mg or rosuvastatin 20-40 mg, or add PCSK9 inhibitor for very high-risk cases. Some clients on pravastatin for specific reasons (transplant recipient, HIV, muscle intolerance) may need to accept LDL that is above ideal target when higher-intensity statins are contraindicated - then ezetimibe and PCSK9 inhibitor become the escalation options.

Beyond LDL - additional markers

• Non-HDL cholesterol - alternative target; captures all atherogenic particles; target LDL + 30 mg/dL
• ApoB - better measure of atherogenic particle number; useful in diabetic dyslipidaemia
• Lipoprotein(a) - measure once in adult life; not modified by statins
• hsCRP - inflammation marker; not routine
• Triglycerides - if elevated, address separately

The PROSPER trial evidence

PROspective Study of Pravastatin in the Elderly at Risk (Shepherd et al. Lancet 2002) enrolled 5,804 clients aged 70-82 with cardiovascular disease or risk factors. Pravastatin 40 mg daily vs placebo. Mean follow-up 3.2 years. Composite cardiovascular endpoint reduced 15 percent. Established evidence-based statin therapy for older adults. Balanced elderly-specific concerns - similar safety across age subgroups.

Practical considerations in older adults

• Polypharmacy - pravastatin's clean interaction profile is especially helpful
• Muscle symptoms - somewhat less common with pravastatin than lipophilic statins
• Renal function decline - dose reduction for severe CKD (10-20 mg starting)
• Falls risk - some evidence lower on statin (fewer syncope events)
• Cognitive concerns - PROSPER specifically reassured
• Frailty - reassess benefit; may consider stopping if life expectancy short
• Starting dose - 10-20 mg often appropriate; can titrate up

Deprescribing considerations

• Life expectancy under 2-3 years - statin benefit unlikely to materialise
• Advanced dementia - discuss with family
• Palliative situations - stop
• Weigh residual benefit against pill burden and side effects
• Do not automatically stop based on age alone - PROSPER shows many older adults benefit
• Individual conversation about goals of care

Continue pravastatin during

• Common cold, mild viral illness
• Mild bacterial infections including those requiring most antibiotics (unlike with lovastatin/simvastatin where clarithromycin is contraindicated)
• Simple stomach upset
• Vaccination (Section 27)
• Routine dental work
• Uncomplicated urinary infections
• Fungal infections including those needing itraconazole (unlike with lovastatin/simvastatin)

Consider temporary pause

• Prescribed clarithromycin - dose limit 40 mg or hold during course
• Severe illness with muscle involvement (viral myositis, extreme rhabdomyolysis risk)
• Severe hepatitis with clearly elevated ALT
• Major surgery or trauma with prolonged NPO
• Acute kidney injury during severe illness

Seek medical review during illness if

• 🔴 Severe muscle pain or weakness
• 🔴 Dark urine
• 🔴 Yellow skin or eyes
• 🔴 Severe nausea and abdominal pain
• 🔴 New severe fatigue or malaise
• 🔴 Reduced urine output during severe illness

Standard vaccinations to prioritise

• Annual influenza vaccine - reduces cardiovascular events during flu season
• Pneumococcal vaccines - age or condition based
• COVID-19 vaccines - per current recommendations
• Shingles (herpes zoster) - Shingrix from age 50
• RSV vaccine - for eligible older adults
• Td/Tdap - tetanus booster every 10 years

Cardiovascular benefit of influenza vaccination

Multiple studies show influenza vaccination reduces cardiovascular events in clients with atherosclerotic disease. Do not skip flu vaccination on account of cardiovascular disease - the opposite is indicated.

Special considerations

• Continue pravastatin around vaccination
• Post-vaccination muscle soreness at injection site is not statin muscle problem
• Transplant recipients on pravastatin - individualised vaccination approach; avoid live vaccines
• HIV clients on pravastatin - standard vaccination approach adjusted for immune status
• Travel vaccinations proceed normally

The 2021 FDA update

Historically statins carried the strongest "Category X" contraindication in pregnancy based on limited animal data suggesting teratogenicity. Larger observational studies did not confirm meaningful human teratogenic effect. The 2021 FDA update removed the absolute contraindication, moving to individualised assessment. The change was driven by the recognition that some women (particularly with familial hypercholesterolaemia or established ASCVD) may benefit from continued statin therapy during pregnancy, and that stopping unnecessarily may carry cardiovascular risk.

Current approach

• Most women: stop pravastatin during pregnancy planning - cardiovascular benefit accrues over years and pregnancy is relatively brief
• Homozygous FH or severe atherosclerotic disease: continued statin may be appropriate; specialist input
• Discuss with lipid specialist before conception planning
• Stop pravastatin when actively trying to conceive (usually)
• Reassure if inadvertent early pregnancy exposure - actual teratogenic risk appears low
• Restart after delivery and after breastfeeding period

Pregnancy in transplant recipients on pravastatin

• Transplant clients on cyclosporine and pravastatin considering pregnancy - specialist input essential
• Cyclosporine has its own pregnancy considerations
• Individual assessment of cardiovascular risk vs pregnancy
• Multidisciplinary team involvement

Contraception

• Reliable contraception standard for reproductive-age women on statin
• Pravastatin does not reduce hormonal contraceptive effectiveness
• No significant contraceptive interaction
• Discussion of pregnancy plans at each annual review

The concern

• Statins theoretically could interfere with infant cholesterol synthesis
• Cholesterol is essential for infant brain and hormone development
• Direct milk transfer data limited
• Historical caution has been to avoid

Practical approach

• Default recommendation: avoid pravastatin during breastfeeding
• Duration of avoidance: throughout breastfeeding, restart after weaning
• Cardiovascular benefit continues over years - short pause for breastfeeding period is generally acceptable
• Homozygous FH or severe disease - specialist input; may need to continue
• Alternative for the exceptional case: bile acid sequestrants (cholestyramine) not systemically absorbed and are compatible with breastfeeding

Postpartum planning

• Diet, weight, exercise attention during breastfeeding period
• Blood pressure management
• Plan for restarting pravastatin at weaning
• Lipid reassessment 6-12 weeks postpartum
• Reproductive planning discussion

General approach

• Continue pravastatin up to and including day of surgery in most cases
• Take with sip of water on morning of surgery if oral intake permitted
• Resume same day or next day post-op when oral intake resumes
• Perioperative statin therapy is associated with reduced perioperative cardiac events in non-cardiac surgery

Specific situations

• Cardiac surgery - continue perioperatively; associated with reduced postop AF and other complications
• Vascular surgery - particularly important to continue; may add if not already on
• Transplant surgery - transplant clients often already on pravastatin; continue
• Extended NPO - can pause for a few days if truly no oral access
• Post-op AKI - reassess; pravastatin has some renal excretion
• Perioperative clarithromycin - dose limit pravastatin during course
• Dental work - no change
• Endoscopy - no change usually

Preoperative statin initiation

In clients undergoing high-risk vascular surgery who are not already on statin, initiation preoperatively may be considered. Best evidence in vascular and cardiac surgery. Timing should allow at least 1-2 weeks for effect before surgery when possible.

Equipotent statin doses

When to switch from pravastatin

• Need for high-intensity therapy - switch to atorvastatin 40-80 mg or rosuvastatin 20-40 mg (if interactions allow)
• LDL not at target on 80 mg + ezetimibe - consider higher-intensity statin
• Muscle symptoms persistent (rare on pravastatin) - try rosuvastatin (also hydrophilic)

When to switch TO pravastatin

• Muscle symptoms on lipophilic statin (atorvastatin, simvastatin)
• Starting cyclosporine (transplant recipient)
• Starting HIV protease inhibitor
• Chronic need for CYP3A4-inhibiting medication
• Older adult on complex polypharmacy
• Cognitive concerns (though evidence does not support cognitive harm)

Add-on therapies when LDL not at target

• Ezetimibe 10 mg daily - 20-25 percent additional LDL reduction; first-line add-on; IMPROVE-IT trial evidence
• Bempedoic acid - ATP citrate lyase inhibitor; 20-25 percent LDL reduction; useful in statin-intolerant clients
• PCSK9 inhibitor (evolocumab, alirocumab) - 50-60 percent additional LDL; injections every 2-4 weeks; FOURIER, ODYSSEY trial evidence
• Inclisiran - PCSK9 siRNA; twice-yearly injection; ORION trial evidence
• Icosapent ethyl - if high triglycerides + CV risk; REDUCE-IT evidence
• Bile acid sequestrants (cholestyramine, colesevelam) - modest additive; often poorly tolerated

Typical escalation ladder

1. Pravastatin 40 mg
2. Increase to 80 mg
3. Add ezetimibe 10 mg
4. If still not at target and no contraindication - switch to atorvastatin or rosuvastatin high-intensity
5. If interactions prevent higher-intensity statin - add PCSK9 inhibitor or inclisiran
6. Consider bempedoic acid combination

🔴 Absolute contraindications

• Active liver disease - decompensated cirrhosis; acute hepatitis
• Unexplained persistent ALT elevation over 3x normal
• Known hypersensitivity to pravastatin
• Pregnancy - relative rather than absolute after 2021 FDA update (Section 28)
• Breastfeeding - generally avoided (Section 29)

Relative contraindications - careful assessment

• Prior severe statin-associated myopathy on other statin
• History of immune-mediated necrotising myopathy on any statin
• Very advanced frailty or short life expectancy
• Alcohol use disorder
• Severe untreated hypothyroidism (treat first)
• Severe CKD - dose reduction
• Cyclosporine - dose limit rather than avoid
• Concurrent gemfibrozil - avoid or use with caution

Not contraindications (unlike lipophilic statins)

• Grapefruit juice consumption - no interaction
• Concurrent itraconazole, ketoconazole - minimal concern
• Concurrent HIV protease inhibitors - preferred statin option
• Concurrent diltiazem, verapamil, amiodarone - little concern
• Concurrent fluconazole - no significant concern
• Fatty liver disease (NAFLD) - pravastatin often improves it
• Compensated cirrhosis - often safe with monitoring
• Diabetes - actually a strong indication
• Older age alone
• Mild ALT elevation

Storage rules

• Room temperature under 25 C
• Original packaging protects from light and moisture
• Not in bathroom, kitchen shelf near stove, or hot car
• Out of sight of children (except when specifically prescribed for paediatric HeFH)
• Do not use past printed expiry
• Return unused tablets to pharmacy at end of treatment or if expired

Travel tips

• Enough tablets for the whole trip plus 5-7 extra days
• Split supply between carry-on and checked luggage on flights
• Keep in original box with prescription label at customs
• Time zone changes - take at usual local time; missing one dose is fine
• Travel insurance including chronic medication cover
• Note pharmacies at destination for emergency refill
• No grapefruit juice concern - enjoy hotel breakfasts

Yearly review checklist

• Lipid panel - LDL at target?
• HbA1c or fasting glucose
• Renal function
• Blood pressure
• Weight and lifestyle status
• Symptom review - muscle, cognitive, gastrointestinal
• Medication reconciliation - cyclosporine? clarithromycin?
• Overall cardiovascular risk reassessment
• Consider if higher-intensity therapy needed and interactions permit
• Vaccination status - flu, pneumococcal, shingles
• Alcohol pattern review
• Diet and exercise coaching

Long-term outlook

Pravachol therapy is typically lifelong for most clients on it. Cardiovascular benefit accrues over years and is maintained by continued therapy. WOSCOPS 20-year follow-up demonstrated durable benefit long after trial completion - the "legacy effect". Most clients tolerate it well and remain on stable doses for decades. Regular annual review keeps therapy tuned, catches any emerging concerns, and reinforces the ongoing benefit.